Monday, December 23, 2024
HomeTagsClinical program

clinical program

Latigo Reports Positive Phase 1 Data & appoints Neil Singla as New CMO

Latigo Biotherapeutics Inc. announced positive Phase 1 results for LTG-001, its lead potential best-in-class non-opioid pain medicine candidate. In a Phase 1 first-in-human clinical...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics